Formycon
Manufacturing · Germany · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Fraunhoferstr. 15, Planegg, Bavaria, 821...Phone Number
+49 89864667100Website
www.formycon.comRevenue
$85.9 MillionStock Symbol
NNDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Formycon
Formycon AG is a global, independent developer of biosimilars, dedicated to improving patient access to high-quality, safe, and affordable biological medicines. The company focuses on creating sustainable value for investors while contributing to the growth of the biosimilars market. Formycon's sustainability strategy aims to enhance the positive impacts of its operations and effectively mitigate sustainability-related risks. Their target clients include patients in need of biologic treatments and investors seeking opportunities in the biosimilars sector.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Formycon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Formycon
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Formycon recently announced quarterly report
Click to see if Formycon had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Formycon has new funding data
Product Launch: Get notified when Formycon launches new products
Check out if Formycon is spiking on competitors!
Formycon, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Formycon has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Formycon is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Formycon is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Formycon.
Formycon Tech Stack
A closer look at the technologies used by Formycon
Most Recent Scoops
Earnings
Formycon has reported milestone revenues of EUR 14.3 million for H1 2026, primarily attributable to deferred milestones recognized under FYB206 partnering agreements for North America and rest of world, as well as a one-off FYB202 milestone related to the auto-injector approval in the European Union.
Earnings, Finance
Earnings
Formycon has reported a significant reduction in R&D expenses for H1 2026, primarily driven by the capitalization of FYB208 costs following the achievement of technical proof of similarity in fall 2025, with FYB210 currently representing the most relevant remaining R&D cost asset.
Research & Development, Accounting, Financial Reporting, Finance
Earnings
Formycon has reported revenues for H1 2026 that increased nearly three times compared to H1 2025, driven primarily by milestones and royalties from FYB202 and FYB206, reflecting a significant transformation toward commercialization-driven revenue.
Earnings, Finance
Project
Formycon has successfully completed the clinical program for FYB206, its biosimilar to Keytruda, in June 2026, following the confirmation of pharmacokinetic equivalence versus the reference product in February 2026, with the resulting data package forming a key element of the regulatory dossier currently in preparation.
Pharmaceuticals, Clinical Operations
Earnings
Earnings, Finance, Financial Operations
Formycon News & Media
Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
AHMEDABAD, India and PLANEGG-MARTINSRIED, Germany, Dec. 9, 2025 /PRNewswire/ -- Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an international presence, today announced that its wholly owned subsidiary, Zydus...Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today jointly announced that they have entered into a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda®1 (Pembrolizumab), in the U.S. and Canada.Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
PLANEGG-MARTINSRIED, Germany and AMMAN, Jordan, Dec. 4, 2025 /PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar candidate...Formycon AG (FYBGF) Q3 2025 Earnings Call Transcript
Formycon AG (OTC:FYBGF) Q3 2025 Earnings Call November 13, 2025 9:00 AM ESTCompany ParticipantsStefan Glombitza - CEO, COO & Chair of the Executive...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Formycon
Sign Up For FreeTo access detailed company insights
Formycon AG is a global, independent developer of biosimilars, dedicated to improving patient access to high-quality, safe, and affordable biological medicines. The company focuses on creating sustainable value for investors while contributing to the growth of the biosimilars market. Formycon's sustainability strategy aims to enhance the positive i... Read More
